Aptahem reports top line results from the FIH study with Apta-1
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, today announces top line results from the First in Human (FIH) study. The aim of the study was to evaluate safety and tolerability with the company’s lead candidate Apta-1 which was performed as a dose escalating study in healthy volunteers.The unblinded data from the study shows that Apta-1 has been well tolerated in the given doses. No serious side effects were seen and all participants fulfilled the study. In the additional analyzes that were performed during